ClinicalTrials.gg
RecruitingNCT04481256TAPESTRYUpdated Jul 26, 2024

TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY

An interventional study of External beam radiotherapy and Bintrafusp alfa in Carcinoma, Squamous Cell and Oesophageal Cancer, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-26.

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Nov 2020; still recruiting 6 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
49
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Carcinoma, Squamous Cell with a site in Netherlands — 4 open to participants now, 9 under way, 2 of them phase 3. Carcinoma, Squamous Cell · Netherlands.

Planned enrollment
9th of 13
49 · median 198
Started
2020
with 2 others
No phase
2 of 21
1 open now
Registered
12th of 21
by date
Lead sponsor
2 of 21
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Among the 21 studies in Carcinoma, Squamous Cell with a site in Netherlands, this one is the 9th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2020, is one of 2 with no phase, and was the 12th registered.

Carcinoma, Squamous Cell

629 studies on the registry are indexed under Carcinoma, Squamous Cell; 135 are open to participants now.

Browse Carcinoma, Squamous Cell studies →

Open to participants now

4 of the 21 studies in Carcinoma, Squamous Cell with a site in Netherlands are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 102 Carcinoma, Squamous Cell studies recruiting now, 86 (84%) set no upper age limit and 8 (8%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Carcinoma, Squamous Cell with a site in Netherlands, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the feasibility of treatment with bintrafusp alfa combined with definitive chemoradiation (carboplatin, paclitaxel and radiation) in patients with squamous cell carcinoma of the esophagus or gastroesophageal junction.

Read the detailed description

Non-randomized feasibility study with paclitaxel, carboplatin, bintrafusp alfa, and radiation. Paclitaxel 50 mg/m2 and carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36. Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg. External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy.

03

Conditions studied

  • Carcinoma, Squamous Cell
  • Oesophageal Cancer

Keywords

  • Definitive chemoradiation
  • TGF-beta inhibition
  • PDL-1 ihibition
  • feasability
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven squamous cell carcinoma of the esophagus or gastro esophageal junction.
  • Surgically irresectable (T1-T4a, N0 or N+, M0), as determined by Endoscopic Ultra Sound (EUS), PET scan and diagnostic CT scan of neck, thorax and abdomen. Patients with M1 disease solely on the basis of supraclavicular are eligible. Patients with resectable tumors refusing radical surgery are eligible.
  • Locoregional recurrences without distant metastasis after surgery alone or endoscopical resection
  • Locoregional recurrences without distant metastasis after chemoradiation + resection or definitive chemoradiation outside the previously irradiated area, provided that full dose of radiation can safely be delivered.
  • Tumors that cannot be passed with an endoscope for endoscopic ultrasound are eligible if all other criteria are fulfilled.
  • If the tumor extends below the gastroesophageal (GE) junction into the proximal stomach, the bulk of the tumor must involve the esophagus or GE junction.
  • Age ≥ 18.
  • performance status 0-2 (cf. Appendix A).
  • Adequate hematological, renal and hepatic functions defined as:

    • Neutrophils ≥ 1.5 x 109/L
    • ≥ 100 x 109/L
    • ≥ 5.6 mmol
    • Total ≤ 1.5 x upper normal limit
    • ASAT and ALAT ≤ 1.5 x upper normal limit, Alkaline Phosphatase ≤ 2.5 x upper normal limit.
    • PT () ≤ 1.5 x upper normal limit and aPTT ≤ 1.5 x upper normal limit.
    • (Cockroft) > 60 ml/min
  • Written, voluntary
  • Patients must be accessible to management and follow-up in the treatment center

Exclusion criteria

Exclusion Criteria:

  • Past or current history of other than entry diagnosis interfering with prognosis of esophageal cancer.
  • Patient with tracheo-esophageal fistula or extension into the mucosal layer of the trachea, highly at risk to develop fistula. Thus, tumor extension to the trachea is allowed, but not through the trachea.
  • Patients with pathological lymph nodes at both supraclavicular and truncus coeliacus level.
  • Pregnancy (positive serum pregnancy test), planning to become pregnant, and lactation.
  • Patient (male or female) in the reproductive age is not willing to use highly effective methods of (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment.
  • Previous chemotherapy, radiation and/or treatment with for the currently present esophageal tumor.
  • Previous chemotherapy and/or treatment with targeted agents and/or checkpoint inhibitors for other forms of cancer within the last six months.
  • Previous radiation to the mediastinum precluding full dose radiation of the currently present esophageal tumor.
  • Persisting grade >1 5.0 toxicity (except alopecia and vitiligo) related to prior therapy; however, grade ≤2 sensory neuropathy is acceptable.
  • Presence of an esophageal stent.
  • History of bleeding diathesis or major bleeding event (grade ≥ 2) in the month prior to first dose of trial treatment.
  • Current use of direct oral anticoagulants or coumarins.
  • cardiovascular disease precluding safe treatment with chemoradiation.
  • Evidence of pulmonary fibrosis and/or clinically significant impairment of lung function precluding safe treatment with chemoradiation. In case of doubt about pulmonary function, a lung function test should be performed and, in case of abnormalities, discussed with the principle investigator.
  • Serious underlying medical condition which would impair the ability of the patient to receive the planned treatment, including prior allergic reactions to drugs containing cremophor, such as teniposide or cyclosporine.
  • Mental status that would prohibit the understanding and giving of .
  • Inadequate caloric- and/or fluid intake despite consultation of a dietician and/or tube feeding.
  • Has an active disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, , or drugs). Replacement therapy (e.g., thyroxine for patients with a history of autoimmune-related hypothyroidism, insulin for patients with type 1 diabetes mellitus, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Patients with vitiligo with dermatological manifestations only are eligible to enter the study.
  • A diagnosis of immunodeficiency or is receiving systemic steroid therapy (>10 mg/day prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
  • Diagnosis of unless stable on antiretroviral therapy for at least 4 weeks, no evidence of multi-drug resistance, viral load of \< 400 copies/ml and CD4+ T-cells ≥ 350 cells/µl.
  • Active /. Participants on a stable dose of antiviral therapy with HBV/HCV viral load below the limit of quantification are eligible.
  • Evidence of interstitial lung disease or active, non-infectious pneumonitis.
  • An active infection requiring systemic therapy, which has not resolved 3 days (simple infection such as cystitis) to 7 days (severe infection such as pyelonephritis) prior to the first dose of trial treatment.
  • Administration of a within 30 days prior to the first dose of trial treatment. Seasonal flu vaccines that do not contain a live virus are permitted.
  • Patients with prior allogeneic stem cell or solid organ transplantation.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (estimated)

Study arms

  • Experimental
    1 Bintrafusp alfa, Paclitaxal, Carboplatin, Radiotherapy

    Non-randomized feasibility study with paclitaxel, carboplatin, bintrafusp alfa, and radiation. Paclitaxel 50 mg/m2 and carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36. Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg. External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy

    Radiation: External beam radiotherapy · Drug: Bintrafusp alfa · Drug: Paclitaxel · Drug: Carboplatin

Interventions

  • RadiationExternal beam radiotherapy

    External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy

  • Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg.

    Also known as: M7824

  • Paclitaxel 50 mg/m2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.

    Also known as: Taxol

  • Carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.

06

What researchers measure

Primary outcomes

  1. Feasibility difined as the percentage of patients completing at least two cycles of bintrafusp alfa

    The primary outcome of this study is the percentage of patients that completes at least two cycles of bintrafusp alfa together with their chemoradiotherapy regimen.

    Time frame: 36 months

Secondary outcomes

  1. Incidence and severity of toxicity

    Incidence and severity of toxicity defined according to CTCAE v5 and and Radiation Oncology Group (RTOG) criteria.

    Time frame: 36 months

  2. Percentage completion

    Percentage completion of chemotherapy and radiation treatment

    Time frame: 36 months

  3. Percentage withdrawal rate

    Percentage withdrawal rate from chemoradiation due to bintrafusp alfa related complications

    Time frame: 36 months

  4. locoregional progression

    Infield locoregional progression free survival

    Time frame: 36 months

  5. progression

    Any progression free survival

    Time frame: 36 months

  6. Survival

    Overall survival

    Time frame: 36 months

  7. Quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ C30))

    Overall Quality of life ranging from 0-100 with 100 being best Quality of Life with special focus on dysphagia

    Time frame: 36 months

  8. adverse events

    To determine the number and grade of adverse events of bintrafusp alfa combined with chemoradiotherapy according to NCI common toxicity criteria (CTC) version 5

    Time frame: 36 months

Other outcomes

  1. Biomarker

    To perform exploratory biomarker analyses for treatment response

    Time frame: 54 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Sep 2025, 57 months after the start.

Of 53 interventional studies with no phase under Carcinoma, Squamous Cell, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 137. This study's planned 57 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2020
First posted
Jul 22, 2020
StartActual
Nov 11, 2020
Primary completionEst.
Sep 1, 2025
CompletionEst.
Sep 1, 2030
Last update
Jul 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04481256
Collaborators
UMC Utrecht, Catharina Ziekenhuis Eindhoven, Institute Verbeeten, Elisabeth-TweeSteden Ziekenhuis, Leiden University Medical Center, Radiotherapeutic Institute Friesland, Medical Centre Leeuwarden, Radiotherapy Group Deventer, Deventer Ziekenhuis, Rijnstate Hospital, Erasmus Medical Center, The Netherlands Cancer Institute, Isala, University Medical Center Groningen, Ziekenhuisgroep Twente
Responsible party
Hanneke W. M. van Laarhoven (Prof. dr., Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Jul 22, 2020
Start date
Nov 11, 2020
Primary completion
Sep 1, 2025 (estimated)
Completion
Sep 1, 2030 (estimated)
Last update
Jul 26, 2024

Study contacts

Linde M Veen, MD
Contact
l.veen1@amsterdamumc.nl
+31 20 4443312
Hanneke WM van Laarhoven, MD, PhD
Contact
h.vanlaarhoven@amsterdamumc.nl
+31 20 5665955
Hanneke WM van Laarhoven, MD,PhD
principal investigator · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bintrafusp alfa

Start the discussion